Suttie Stuart, McAteer Dympna, Sheehan Margaret, Nicolson Marianne, Schweiger Lutz, Hammonds Solveig, Smith Timothy, Welch Andrew, Park Kenneth
Department of Surgery, Aberdeen Royal Infirmary, Foresterhill, Aberdeen, UK, AB25 2ZN.
Department of Radiology, Aberdeen Royal Infirmary, Foresterhill, Aberdeen, UK, AB25 2ZN.
World J Oncol. 2010 Apr;1(2):66-67. doi: 10.4021/wjon2010.04.201w. Epub 2010 Apr 30.
To determine the utility of F-18-FDG and C-11-Choline uptake, in patients with esophageal and esophago-gastric junction tumors who are to undergo either neo-adjuvant or palliative chemotherapy, in predicting response (pathological and survival).
Eighteen patients with biopsy proven cancer were recruited prospectively. Patients underwent PET imaging before and during the first cycle of chemotherapy (seven and 14 days) with both F-18-FDG and C-11-Choline. Tracer uptake was quantified using Standardized Uptake Values. Pathological tumor response was determined using the Mandard criteria. Cellular proliferation was determined using ki-67 immunohistochemistry. Relationships between tracer uptake and response, one-year survival and cellular proliferation were determined.
All 18 tumors were imaged by F-18-FDG PET compared to 16/18 with C-11-Choline. Change in uptake of either tracer did not correlate with pathological response. Pathological response did not influence survival (median-survival, responders = 16.1 months; non-responders = 19.0 months, = 0.978). There was no significant correlation of change in tracer uptake with survival. C-11-Choline tumor uptake did not correlate with cellular proliferation.
F-18-FDG PET is superior for imaging of the primary tumor. Neither F-18-FDG nor C-11-Choline PET was able to predict response accurately.
为了确定F-18-氟代脱氧葡萄糖（F-18-FDG）和C-11-胆碱摄取在接受新辅助化疗或姑息化疗的食管及食管胃交界肿瘤患者中预测反应（病理反应和生存）的效用。
前瞻性招募了18例经活检证实为癌症的患者。患者在化疗的第一个周期（第7天和第14天）期间及之前分别接受F-18-FDG和C-11-胆碱的PET成像。使用标准化摄取值对示踪剂摄取进行定量。使用曼德尔标准确定病理肿瘤反应。使用ki-67免疫组织化学确定细胞增殖。确定示踪剂摄取与反应、一年生存率和细胞增殖之间的关系。
F-18-FDG PET对所有18个肿瘤进行了成像，而C-11-胆碱对18个中的16个进行了成像。两种示踪剂摄取的变化均与病理反应无关。病理反应不影响生存（中位生存期，反应者 = 16.1个月；无反应者 = 19.0个月，P = 0.978）。示踪剂摄取的变化与生存无显著相关性。C-11-胆碱肿瘤摄取与细胞增殖无关。
F-18-FDG PET在原发性肿瘤成像方面更具优势。F-18-FDG和C-11-胆碱PET均不能准确预测反应。
